In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

Primary esophageal epithelial cells (keratinocytes) from normal human esophagus were established as described previously. 6 Fetal esophageal fibroblasts (FEF) were isolated as previously described ...

San Diego-based iBio, an AI-driven innovator of precision antibody therapies, has announced a licensing agreement with ...

iBio announces licensing agreement with AstralBio for a novel antibody targeting Activin E, potentially aiding weight loss and cardiometabolic health. Bio, Inc. has announced a licensing agreement ...

Bio announced a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, which was discovered using ...

Serum cancer antigen 125, creatine kinase and activin A levels have been studied as possible predictors of pregnancy outcome. However, no single factor has yet been identified to predict the ...

Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to ...

(MENAFN- GlobeNewsWire - Nasdaq) In-Licensing of novel activin E antibody underscores iBio's commitment to delivering meaningful benefits to patients living with obesity and cardiometabolic ...